Fluorouracil and leucovorin for metastatic colorectal cancer.

C. Erlichman

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


We have performed a prospective randomized controlled study of 5-fluorouracil (5FU) + leucovorin versus 5FU alone in patients with metastatic colorectal cancer. The 5FU at a dose of 370 mg/m2/d x 5 days and the leucovorin at a dose of 200 mg/m2/d x 5 days were given every 28 days. The 5FU dose was escalated to equitoxicity in the single agent arm on subsequent studies. The response rate was 33% for the combination and only 7% for 5FU alone. The median survival for 5FU + leucovorin was 12.6 months and 9.6 months for 5FU alone. The dose-limiting toxicity was mucositis with diarrhea being the second most common problem. The combination of 5FU + leucovorin is an effective treatment in the management of patients with metastatic colorectal cancer and should be used as a foundation from which to build upon.

Original languageEnglish (US)
Pages (from-to)38-40
Number of pages3
JournalJournal of chemotherapy (Florence, Italy)
Volume2 Suppl 1
StatePublished - Feb 1990

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases


Dive into the research topics of 'Fluorouracil and leucovorin for metastatic colorectal cancer.'. Together they form a unique fingerprint.

Cite this